NEU 2.90% $19.86 neuren pharmaceuticals limited

Unbelievable...., page-10

  1. 388 Posts.
    lightbulb Created with Sketch. 243
    I think you are right Hottod. When you look at the long list of achievements and positive outcomes, and Neuren has ultimately had no Market Cap recognition, it is as you say, unbelievable. All the management team can do is continue to deliver on the program, this is the only true source of value creation, whether the market is willing to recognise that yet or not.

    The current Sp is a heap of sh!t but you shouldn't have your hard earned $ in this if you don't believe in the technology or the Neuren leadership team. We have seen soaring highs and deep lows time and again. The benefits will only come to those with thick skin and a tough stomach. We will be shaken out time and again before we are done.

    For me I think the board have previously sought financing arrangements other than tapping the market. They sought approval to expand Lang's holding before deciding to go with Lanstead. They didn't at that point look to tap us. With the current SP route I think a CR offers poor value for investors and I would expect the board will recognise that.

    We know with Torreya that they are looking for partnering agreements (or other transactions). This may include an upfront to cover costs until the RPD voucher is available, or a partner (like Acadia) could agree to fund NNZ-2591 development, P2 etc. I think a CR is premature at this point. they have enough cash in the bank to run the Torreya process to ground.

    Maybe you are right on the accuracy of CR forecasts, lets hope they find another way with so many balls in the air and such a sh!tty SP.
 
watchlist Created with Sketch. Add NEU (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.